Un enfoque para el tratamiento de las úlceras de origen vascular: revisión y papel del factor de crecimiento epidérmico

Review of scientific evidence and therapeutic options of recombinant human bioidentical epidermal growth factor (rhEGF) for vascular ulcers. Efficacy, with excellent tolerability and safety has been demonstrated with rhEGF, and it has been considered as an adjuvant or emerging treatment in evidence based clinical practice guidelines. rhEGF is available by magistral prescription, ensuring stability, effectiveness and safety, allowing individualisation (addition of active principles or dose personalisation). Compounds with rhEGF can be considered for managing vascular ulcers.